Around 31% of all adverse events in hospitals are caused by medication-related problems. The use of prescription drugs has increased by 90% over the past 25 years with a consequent increase in ADEs reported to the FDA (National Center for Health Statistics [NCHS], 2012). ADEs, whether from drug–drug or drug–disease interactions, inappropriate prescribing, poor adherence, or medication errors, lead to serious or potentially fatal outcomes for older adults. Between 2004 and 2008, there was a 52% increase in the number of ADEs reported in U.S. hospitals (Lucado, Paez, & Elixhauser, 2008). In U.S. hospitals, ADEs increase costs to patients, healthcare expenditures, length of hospital stay, and morbidity and mortality, yet nearly half are likely preventable. Increase in ADEs has become common partly because of a considerable increase in prescription drug use. Analysis from NCHS reported that older adults taking five or more prescription drugs within a 30-day span increased by 28.4% between 1988 and 1994 and between 2013 and 2014 (National Center for Health Statistics, 2016–2017). Overall, ADEs continue to be a main priority in the U.S. healthcare system.
- Adverse drug events (ADEs): Defined as an injury resulting from medical intervention related to a drug (Kohn et al., 2000). ADEs, compared with medication errors, are a more direct measure of patient harm.
- Medication errors: Refer to any “preventable event that may cause or lead to inappropriate medication use or patient harm while the medication is in the control of a health care professional, patient, or consumer” (National Coordinating Council for Medication Error Reporting and Prevention, n.d.-a, para. 2).
- Adverse drug reaction: Any noxious or unintended and undesired effect of a drug that occurs at normal human doses for prophylaxis, diagnosis, or therapy. Inappropriate prescribing of high-risk medication to older adults and medication errors are all considered iatrogenic (World Health Organization, 1972). They are also preventable causes of harm to patients (Lavan & Gallagher, 2016).
- Drug–drug interactions: When one therapeutic agent alters either the concentration (pharmacokinetic interactions) or the biological effect of another agent or pharmacodynamic interactions (Levinson, 2018).
- Medication adherence: Defined as the extent to which a person’s medication-taking behavior corresponds with agreed recommendations of a healthcare provider (Sabaté, 2003). It is also a two-way form of communication in which a patient and medical provider assume active roles in fulfilling the set therapeutic regimen (Lo et al., 2016).
- Drug–disease interactions: Undesired drug effects (exacerbation of a disease or condition caused by a drug) that occur in patients with certain disease states. Common drug–disease interaction is aspirin given in peptic ulcer disease and beta blockers given in diabetes (Salvi et al., 2012).
- Pharmacokinetics: The time course of absorption, distribution across compartments, metabolism, and excretion of drugs in the body. The metabolism and excretion of many drugs decrease, and the physiological changes of aging require dose adjustment for some drugs (Levinson, 2018; Steinman & Holmes, 2014).
- Pharmacodynamics: The response of the body to the drug that is affected by receptor binding, postreceptor effects, and chemical interactions. Pharmacodynamic problems occur when two drugs act at the same or interrelated receptor sites, resulting in additive, synergistic, or antagonistic effects. The effects of two or more drugs together can be either additive (combination of drugs “add up” to increase effect), synergistic (one agent magnifies the effect of the other), or antagonistic (one medication inhibits the effect of the other; Steinman & Holmes, 2014).
- Medication reconciliation: Defined by The Joint Commission (2010) as “the process of comparing the medications a patient is taking (and should be taking) with newly ordered medications” (p. 4). It is a process of comparing the patient’s current medication regimen against the physician’s admission, transfer, and/or discharge orders to identify discrepancies (The Joint Commission, 2010).
- Older adults are the greatest consumers of medications, with older Americans taking three OTC medications and up to six or more prescription medications (Petrovic et al., 2012). Half of all prescriptions are prescribed to older adults, with those in office practices taking six or greater medications. Medicare patients (>65 y.o.) have the highest rates of ADEs, representing 75.3 per 10,000 discharges.
- Older adults experience a 10.7% prevalence rate of hospital admissions caused by ADRs; however, a confounding factor in the accuracy is the different methods and studies employed to gather the data (Kongkaew et al., 2013).
Older adults, especially frail older adults, become increasingly susceptible to ADEs as they age (Hubbard et al., 2013). Physiological change and characteristics of aging predispose older adults to experience adverse events. ADEs increase the costs, length of hospital stay, and mortality yet often go unreported, and nearly half are likely preventable (Levinson, 2018; Salvi et al., 2012). Persons older than age 65 experience medication-related problems for five major reasons:
- Age-related physiological changes that result in altered pharmacokinetics and pharmacodynamics (Levinson, 2018; Rochon, 2019; Steinman & Holmes, 2014)
- Polypharmacy (multiple medications) that are often prescribed by multiple providers (Fulton & Riley Allen, 2005; Qato et al., 2016)
- Therapeutic failures—over or underdosing of medications (more than or less than a therapeutic dosage; Fillit et al., 2016; Marcum et al., 2012)
- Medication consumption for the treatment of symptoms that are not disease dependent or specific self-medication and/or prescribing cascades (Rochon, 2019)
- Iatrogenic causes such as:
- ADRs, including drug–drug or drug–disease interactions (Heuberger, 2012).
- Inappropriate prescribing for older adults (Hamilton et al., 2011).
- Problems with medication adherence (Lo et al., 2016; Marcum et al., 2012; Steinman & Hanlon, 2010; Steinman & Holmes, 2014).
- Medication errors (Charles et al., 2014; Steinman et al., 2011).
ASSESSMENT TOOLS AND STRATEGIES
A. Assessment Tools
- Beers Criteria: American Geriatrics Society (2019) Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. Use to assess medication list for medications that should generally be avoided in older adults (American Geriatrics Society, 2019).
- STOPP Criteria: Screening Tool of Older Persons—used to identify potentially inappropriate medications (Gallagher et al., 2011; Hamilton et al., 2011)
- START Criteria: Screening Tools to Alert Doctors to the Right Treatment—use criteria to identify medications that are underutilized and potential prescription omissions (Gallagher et al., 2011; Lang et al., 2012).
- Drug–Drug Interactions: Tables 24.1 and 24.2. Review list of common medications known to interact with other medications or using computer decision-support and computer drug–drug interaction alerts (Clyne, Bradley, Hughes, Fahey, & Lapane, 2012).
- Cockroft–Gault Formula—Exhibit 24.1. Useful for estimating creatinine clearance based on age, weight, and serum creatinine levels (Terrell et al., 2006). A creatinine clearance of less than 50 mL/min places older adults at risk for ADEs (Fouts, Hanlon, Pieper, Perfetto, & Fernberg, 1997).
- Brown Bag Method—used to assess all medications. Ask older adult to place all medications, OTCs, and herbal remedies in a bag and bring it to the hospital/other care setting to ensure med list is accurate (Nathan et al., 1999; Weiss et al., 2016).
- Drug Regimen Unassisted Grading Scale (DRUGS) Tool—Used at transfer to other levels of care. Standardized method for assessing potential medication adherence problems. This requires a higher level of functioning (Edelberg et al., 1999; Hutchison, Jones, West, & Wei, 2006).
- Functional capacity—Evaluate activities of daily living (ADL) and independent activities of daily living (IADL), Use Mini-Cog or Mini-Mental State Exam (MMSE) and evaluate ability to self-administer medications (see Chapter 9, Assessing Cognitive Function in the Older Adult and Chapter 10, Assessment of Physical Function in the Older Adult).
B. Assessment Strategies
National Coordinating Council (NCC) for Medication Error Reporting and Prevention (MERP) index for categorizing medication errors.
Note: Harm, impairment of the physical, emotional, or psychological function or structure of the body and/or pain resulting therefrom; Monitoring, To observe or record relevant psychological signs; Intervention, May include change in therapy or active medical/surgical treatment; Intervention Necessary to Sustain Life, Includes cardiovascular and respiratory support (e.g., CPR, defibrillation, intubation, etc.)
Source: National Coordinating Council for Medication Error Reporting and Prevention. (n.d.-b). Types of medication errors. Retrieved from https://www.nccmerp.org/types-medication-errors.
See Figure 24.4
- Identify aging changes in pharmacokinetics and pharmacodynamics when assessing medications in older adults (Levinson, 2018; Steinman & Holmes, 2014).
- Perform a Comprehensive Geriatric Assessment: Geriatric evaluation and management reduced inappropriate and unnecessary medications. A comprehensive assessment is important as it is a more global assessment that ensures a more specific plan for each single patient (Avelino-Silva et al., 2014; Petrovic et al., 2012).
- Perform a comprehensive medication history (FitzGerald, 2009)
- Currently prescribed drugs, doses, route of administration, frequency taken, and duration of treatment
- Over-the-counter drugs and herbal remedies
- Drugs taken in the recent past
- Previous drug hypersensitivity reaction and the nature (rash or anaphylaxis)
- Previous adverse drug reactions and nature
- Adherence to therapy (what medications are you having difficulty with? Or how many pills have you missed this week/month?)
- Obtain up-to-date medication list from primary provider or pharmacy
- Check with pharmacy regarding prior ADRs and last order dates for each medication
- Inspect drugs and their container for name, dosage, and number of meds taken since dispensed
- The comprehensive medication assessment must include a formal evaluation of the ability to manage medications on an individual basis (Topinková et al., 2012). Perform at discharge and at times between transition between units
- Regular medication review to evaluate list for PIMs/PIPs (Beers Criteria and STOPP Criteria); consider drugs to discontinue (Gallagher et al., 2011).
- Evaluate for patient-related and medication-related risk factors for ADRs (see Box 24.1).
- Perform medication reconciliation at admission, discharge, transfers, and transitions to other levels of care in consultation with a pharmacist, geriatric expert, or computer-based program (Frankenthal et al., 2014).
- At discharge from hospital, use appropriate tools to assess individual’s ability to self-administer medications (Ho, Bryson, & Rumsfeld, 2009).
INTERVENTIONS AND NURSING CARE STRATEGIES
A. Reducing ADEs (during and post hospitalization)
- Patient/Family-centered care and decision-making include collaboration with interdisciplinary team members. Patients should be given the necessary information and the opportunity to exercise the degree of control they choose over healthcare decisions that affect them. Patients involved in decision-making are less likely to make decisions that may lead to ADRs, such as abruptly discontinuing a medication that should be tapered off (Parchman, Zeber, & Palmer, 2010).
- Comprehensive Geriatric Prescribing:
- Evaluate prescriptions for benefit versus harm.
- Choose the safest and best medication for the individual based on geriatric assessment and goals of care.
- Prior to prescribing, consider the individual’s comorbidities such as liver or kidney disease or a disease that may interact with a drug (Salvi et al., 2012).
- Prescribing principles. Although bedside nurses are not involved in prescribing, they are involved in reviewing and signing off medications, and thus should be aware of prescribing principles.
- Monitoring for appropriate prescribing and alerting the prescriber to potential problem areas; monitoring for and reporting lab/drug levels to primary provider; monitoring for toxicity and medication effectiveness; and seeking consultation when necessary (Rochon, 2019).
- Reduce the dose. “Start low and go slow,” providing the lowest possible dose and slow upward titration to obtain clinical benefit; many ADEs are dose related (Rochon, 2019). Primary provider should be notified if the dosage ordered is higher than the recommended starting dose (e.g., digoxin maximum dose less than 0.125 mg for treatment of systolic heart failure).
- Discontinue unnecessary therapy. Prescribers are often reluctant to stop medications, especially if they did not initiate the treatment. This practice increases the risk for an adverse event (Rochon, 2019; e.g., therapeutic activity kit for agitation).
- Recommend safer drugs. Avoid drugs that are likely to be associated with adverse outcomes (review Beers Criteria).
- Assess renal function using the Cockroft–Gault formula (for renally cleared drugs) to determine accurate dosage prior to prescribing, such as for many routinely prescribed intravenous (IV) antibiotics. Dosage recommendations are available based on this formula and are presented in common prescribing resources.
- Optimize drug regimen. When prescribing medications, focus on risk versus benefit where the expected health benefit (e.g., relief of agitation in dementia with psychosis) exceeds the expected negative consequences (e.g., morbidity and mortality from falls that result in hip fracture).
- Initiation of new medication. Assess risk factors for ADRs, potential drug–disease and drug–drug interactions, correct drug dosages, and follow-up to evaluate response to new medication.
- Avoid the prescribing cascade. Avoid the prescribing cascade by first considering any new symptom as being an adverse effect of a current medication prior to adding a new medication.
- Avoid inappropriate medications. Review Beers and STOPP criteria for PIMs, drug–disease interactions, and potential drug–drug interactions (see AGS website in references).
- Evaluate for patient concern regarding difficulties in adherence to medication (Steinman & Hanlon, 2010).
B. Computerized Order Entry and Decision-Support Systems
- Monitor and attend to alerts for potential drug–drug interactions
- Pharmacist-based support of CPOE and electronic prescriptions direct to pharmacy
- Reminder systems for monitoring (Charles et al., 2014)
C. Monitoring (Steinman et al., 2011)
- Evaluate patient for adverse effects and efficacy after a new medication is started.
- Educate patients about anticipated benefits and potential problems associated with a new drug. Partner with the patient to actively engage as a partner to assess drug effectiveness, adherence, and adverse effects. Partner with the patient to actively engage as a partner to assess drug effectiveness, adherence, and adverse, especially with patients taking drugs with narrow therapeutic ranges.
- Report questionable dosing amounts or schedule and medication allergy prior to medication administration. (See also Documentation of Drug Allergies post hospital.)
- Monitor for drug interactions and inform primary provider of new or recent medications that may be related to the cause.
- Use health information technology (HIT) to monitor labs where available, for example, lab tracing systems.
- Use team-based approaches to monitor medications.
- Risk assessment tools—individualize monitoring based on individual risk.
- Report generated when lab tests are not performed with follow-up mechanism.
- Policy standards that mandate ability to track and report overdue lab tests easily.
A. Patients will:
- Experience fewer adverse outcomes from medication-related events.
- Demonstrate understanding of their medication regimens upon discharge from the hospital and keep an updated medication list.
- Become active members of medication decision-making and monitoring.
B. Healthcare providers will:
- Use a range of interventions to prevent, alleviate, or ameliorate medication problems with older adults, including nonpharmacological and complementary therapies.
- Improve prescribing practices by documenting indications for initiation of new drug therapy, maintaining a current medication list, and documenting response to therapy as well as the need for ongoing treatment and follow-up monitoring.
- Evaluate nature and origins of medication-related problems in a timely manner.
- Increase their knowledge about medication safety in older adults.
- Increase referrals to appropriate practitioners for collaboration and medication safety (e.g., pharmacist, geriatrician, geriatric/gerontological, or psychiatric clinical nurse specialist, nurse practitioner, or consultation-liaison service, social worker, case manager, or interdisciplinary team).
C. Institution will:
- Provide a culture of safety that encourages safe medication practices.
- Provide education to healthcare providers regarding prevention, identification, and reporting of ADRs.
- Make information on ADRs accessible to patients.
- Enhance surveillance and reporting of ADRs using a national surveillance system. Consider use of computerized physician order entry system and drug interaction software.
- Track and report morbidity and mortality related to medication problem.
- Provide a system for medication reconciliation, and follow up its effectiveness regarding rehospitalization rates caused by ADRs.
- Review for careful documentation of iatrogenic medication and other iatrogenic events for continuous quality improvement (CQI).
- Provide ongoing education related to safe medication management for physicians, other licensed independent providers, pharmacists, and nursing staff.
A. Healthcare providers will:
- Provide consistent and appropriate care and follow-up in the presence of a medication-related problem.
- Monitor and evaluate with physical exam and/or laboratory tests (as appropriate) on a regular basis to ensure that the older adult is responding to therapy as expected.
- Review the medications list, including OTC and herbal remedies, regularly and reconcile medications at transitions in care.
- Monitor high-risk medications more frequently for potential adverse events.
B. Institutions will:
- Provide ongoing assessment of staff competence in assessing and intervening for prevention of ADEs.
- Embed reduction of ADEs in the institution’s culture of safety.
RELEVANT PRACTICE GUIDELINES
Medications at Transitions and Clinical Handoffs (MATCH) Toolkit for Reconciliation. (Agency for Healthcare Research and Quality (2012). Medications at transitions and clinical handoffs (MATCH) toolkit for reconciliation [AHRQ Publication No 11(12)-0059]. Rockville, MD. Retrieved from https://www.ahrq.gov/patient-safety/resources/match/index.html
ADE Adverse drug event
ADL Activities of daily living
ADR Adverse drug reactions
CPOE Computerized Provider Order Entry
CPR Cardiopulmonary resuscitation
CQI Continuous quality improvement
DRUGS Drug Regimen Unassisted Grading Scale
FDA U.S. Food and Drug Administration
HIT Health information technology
IADL Instrumental activities of daily living
INR International normalized ratio
MATCH Medications at transitions and clinical handoffs
MERP Medication Error Reporting and Prevention
MMSE Mini-Mental State Exam
NCC National Coordinating Council
NCHS National Center for Health Statistics
PIMs Potentially inappropriate medications
PIPs Potentially inappropriate prescriptions
WHO World Health Organization
Updated: November 2020
Boltz PhD, RN, GNP-BC, FGSA, FAAN, M., Capezuti PhD, RN, FAAN, E., Zwicker DrNP, APRN, BC, D., & Fulmer PhD, RN, FAAN, T. T. (2020). Evidence-Based Geriatric Nursing Protocols for Best Practice (6th ed.). Springer Publishing. Retrieved November 4, 2020, from https://www.springerpub.com/evidence-based-geriatric-nursing-protocols-for-best-practice-9780826188144.html#description
Agency for Healthcare Research and Quality. (2012). Medications at transitions and clinical handoffs (MATCH) toolkit for reconciliation. Retrieved from https://www.ahrq.gov/patient-safety/resources/match/index.html
American Geriatrics Society. (2019). For older people, medications are common; updated AGS Beers Criteria® aims to make sure they’re appropriate, too. Retrieved from https://www.americangeriatrics.org/media-center/news/older-people-medications-are-common-updated-ags-beers-criteriar-aims-make-sure. Evidence Level VI.
Avelino-Silva, T. J., Farfel, J. M., Curiati, J. A., Amaral, J. R., Campora, F., & Jacob-Filho, W. (2014). Comprehensive geriatric assessment predicts mortality and adverse outcomes in hospitalized older adults. BMC Geriatrics, 14(1), 129. doi:10.1186/1471-2318-14-129. Evidence Level IV.
Charles, K., Cannon, M., Hall, R., & Coustasse, A. (2014). Can utilizing a Computerized Provider Order Entry (CPOE) system prevent hospital medical errors and adverse drug events? Perspectives in Health Information Management, 11, 1b. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4272436. Evidence Level V.
Clyne, B., Bradley, M. C., Hughes, C., Fahey, T., & Lapane, K. L. (2012). Electronic prescribing and other forms of technology to reduce inappropriate medication use and polypharmacy in older people: A review of current evidence. Clinics in Geriatric Medicine, 28(2), 301–322. doi:10.1016/j.cger.2012.01.009. Evidence Level I.
Edelberg, H. K., Shallenberger, E., & Wei, J. Y. (1999). Medication management capacity in highly functioning community-living older adults: Detection of early deficits. Journal of the American Geriatrics Society, 47(5), 592–596. doi:10.1111/j.1532-5415.1999.tb02574.x. Evidence Level I.
Fillit, H. M., Rockwood, K., & Young, J. B. (2016). Brocklehurst’s textbook of geriatric medicine and gerontology. Philadelphia, PA: Elsevier Health Sciences. Evidence Level IV.
FitzGerald, R. J. (2009). Medication errors: The importance of an accurate drug history. British Journal of Clinical Pharmacology, 67(6), 671–675. doi:10.1111/j.1365-2125.2009.03424.x. Evidence Level V.
Fouts, M., Hanlon, J., Pieper, C., Perfetto, E., & Fernberg, J. (1997). Identification of elderly nursing facility residents at high risk for drug-related problems. The Consultant Pharmacist: The Journal of the American Society of Consultant Pharmacists, 12, 1103–1111. Evidence Level VI.
Frankenthal, D., Lerman, Y., Kalendaryev, E., & Lerman, Y. (2014). Intervention with the screening tool of older persons potentially inappropriate prescriptions/screening tool to alert doctors to right treatment criteria in elderly residents of a chronic geriatric facility: A randomized clinical trial. Journal of the American Geriatrics Society, 62(9), 1658–1665. doi:10.1111/jgs.12993. Evidence Level II.
Fulton, M. M., & Riley Allen, E. (2005). Polypharmacy in the elderly: A literature review. Journal of the American Academy of Nurse Practitioners, 17(4), 123–132. doi:10.111/j.1041-2972.2005.0020.x. Evidence Level V.
Gallagher, P., O’Connor, M., & O’Mahony, D. (2011). Prevention of potentially inappropriate prescribing for elderly patients: A randomized controlled trial using STOPP/START criteria. Clinical Pharmacology & Therapeutics, 89(6), 845–854. doi:10.1038/clpt.2011.44. Evidence Level II.
Hamilton, H., Gallagher, P., Ryan, C., Byrne, S., & O’Mahony, D. (2011). Potentially inappropriate medications defined by STOPP criteria and the risk of adverse drug events in older hospitalized patients. Archives of Internal Medicine, 171(11), 1013–1019. doi:10.1001/archinternmed.2011.215. Evidence Level V.
Heuberger, R. (2012). Polypharmacy and food-drug interactions among older persons: A review (Vol. 31, pp. 325). Philadelphia, PA: Taylor & Francis. Evidence Level VII.
Ho, P., Bryson, C., & Rumsfeld, J. (2009). Medication adherence: Its importance in cardiovascular outcomes. Circulation, 119(23), 3028–3035. doi:10.1161/CIRCULATIONAHA.108.768986. Evidence Level VI.
Hubbard, R., O’Mahony, M., & Woodhouse, K. (2013). Medication prescribing in frail older people. European Journal of Clinical Pharmacology, 69(3), 319–326. doi:10.1007/s00228-012-1387-2. Evidence Level VI.
Hutchison, L. C., Jones, S. K., West, D. S., & Wei, J. Y. (2006). Assessment of medication management by community-living elderly persons with two standardized assessment tools: A cross-sectional study. The American Journal of Geriatric Pharmacotherapy, 4(2), 144–153. doi:10.1016/j.amjopharm.2006.06.009. Evidence Level IV.
The Joint Commission. (2010). National patient safety goals. Retrieved from http://www.jointcommission.org/. Evidence Level VI.
Kohn, L. T., Corrigan, J. M., & Donaldson, M. S. (Eds.). (2000). To err is human: Building a safer health system (Vol. 6). Washington, DC: National Academies Press. Evidence Level VI.
Kongkaew, C., Hann, M., Mandal, J., Williams, S. D., Metcalfe, D., Noyce, P. R., & Ashcroft, D. M. (2013). Risk factors for hospital admissions associated with adverse drug events. The Journal of Human Pharmacology Drug Therapy, 33(8), 827–837. doi:10.1002/phar.1287. Evidence Level IV.
Lang, P. O., Vogt-Ferrier, N., Hasso, Y., Le Saint, L., Dramé, M., Zekry, D., … Prudent, M. (2012). Interdisciplinary geriatric and psychiatric care reduces potentially inappropriate prescribing in the hospital: Interventional study in 150 acutely ill elderly patients with mental and somatic comorbid conditions. Journal of the American Medical Directors Association, 13(4), 406.e1–406.e7. Retrieved from doi: 10.1016/j.jamda.2011.03.008. Evidence Level IV.
Lavan, A. H., & Gallagher, P. (2016). Predicting risk of adverse drug reactions in older adults. Therapeutic Advances in Drug Safety, 7(1), 11–22. doi:10.1177/2042098615615472. -Evidence Level VI.
Levinson, D. R. (2018). Adverse events in hospitals: National incidence among Medicare beneficiaries. Washington, DC: U.S. Department of Health and Human Services. Retrieved from https://oig.hhs.gov/oei/reports/oei-06-14-00530.asp. Evidence Level IV.
Lo, S. H., Chau, J. P., Woo, J., Thompson, D. R., & Choi, K. C. (2016). Adherence to antihypertensive medication in older adults with hypertension. The Journal of Cardiovascular Nursing, 31(4), 296–303. doi:10.1097/JCN.0000000000000251. Evidence Level VI.
Lucado, A., Paez, K., & Elixhauser, A. (2008). Medication-related adverse outcomes in U.S. hospitals and emergency departments. Retrieved from http://www.hcup-us.ahrq.gov/reports/-statbriefs/sb109.jsp. Evidence Level IV.
Marcum, Z., Pugh, M., Amuan, M. E., Aspinall, S., Handler, S. M., Ruby, C. M., & Hanlon, J. (2012). Prevalence of potentially preventable unplanned hospitalizations caused by therapeutic failures and adverse drug withdrawal events among older veterans. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences, 67(8), 867–874. doi:10.1093/gerona/gls001. Evidence Level VI.
Nathan, A., Goodyer, L., Lovejoy, A., & Rashid, A. (1999). ‘Brown Bag’ Medication reviews as a means of optimizing patients’ use of medication and of identifying potential clinical problems. Family Practice, 16(3), 278–282. doi:10.1093/fampra/16.3.278. Evidence Level IV.
National Center for Health Statistics. (2012). Special feature on socioeconomic status and health. Hyattsville, MD: Author. Retrieved from http://www.cdc.gov/nchs/data/hus/hus11.pdf. Evidence Level VI.
National Center for Health Statistics. (2016–2017). Health, United States: 2016 With Chartbook on long-term trends in health 2017. Hyattsville, MD: Author. Retrieved from https://www.cdc.gov/nchs/data/hus/hus16.pdf. Evidence Level V.
Parchman, M. L., Zeber, J. E., & Palmer, R. F. (2010). Participatory decision making, patient activation, medication adherence, and intermediate clinical outcomes in type 2 diabetes: A STARNet study. The Annals of Family Medicine, 8(5), 410–417. doi:10.1370/afm.1161. Evidence Level V.
Petrovic, M., van der Cammen, T., & Onder, G. (2012). Adverse drug reactions in older people. Drugs & Aging, 29(6), 453–462. doi:10.2165/11631760-000000000-00000. Evidence Level V.
Qato, D. M., Wilder, J., Schumm, L. P., Gillet, V., & Alexander, G. C. (2016). Changes in prescription and over-the-counter medication and dietary supplement use among older adults in the United States, 2005 vs 2011. JAMA Internal Medicine, 176(4), 473–482. doi:10.1001/jamainternmed.2015.8581. Evidence Level III.
Rochon, P. A. (2019). Drug prescribing for older adults. : In K. E. Schmader, & J. Givens (Eds.), UpToDate. Retrieved from https://www.uptodate.com/contents/drug-prescribing-for-older-adults. Evidence Level V.
Sabaté, E. (Ed.). (2003). Adherence to long-term therapies: Evidence for action. Geneva, Switzerland: World Health Organization. Evidence Level V.
Salvi, F., Marchetti, A., D’Angelo, F., Boemi, M., Lattanzio, F., & Cherubini, A. (2012). Adverse drug events as a cause of hospitalization in older adults. Drug Safety, 35(1), 29–45. doi:10.1007/BF03319101. Evidence Level I.
Steinman, M. A., Handler, S. M., Gurwitz, J. H., Schiff, G. D., & Covinsky, K. E. (2011). Beyond the prescription: Medication monitoring and adverse drug events in older adults. Journal of the American Geriatrics Society, 59(8), 1513–1520. doi:10.1111/j.1532-5415.2011.03500.x. Evidence Level VI.
Steinman, M. A., & Hanlon, J. T. (2010). Managing medications in clinically complex elders: “There’s got to be a happy medium.” Journal of the American Medical Association, 304(14), 1592–1601. doi:10.1001/jama.2010.1482. Evidence Level I.
Steinman, M. A., & Holmes, H. M. (2014). Principles of prescribing in older adults (2nd ed.). New York, NY: McGraw-Hill Education. Evidence Level IV.
Terrell, K. M., Heard, K., & Miller, D. K. (2006). Prescribing to older ED patients. The American Journal of Emergency Medicine, 24(4), 468–478. doi:10.1016/j.ajem.2006.01.016. Evidence Level V.
Topinková, E., Baeyens, J. P., Michel, J.-P., & Lang, P.-O. (2012). Evidence-based strategies for the optimization of pharmacotherapy in older people. Drugs & Aging, 29(6), 477–494. doi:10.2165/11632400-000000000-00000. Evidence Level I.
Weiss, B. D., Brega, A. G., LeBlanc, W. G., Mabachi, N. M., Barnard, J., Albright, K., … West, D. R. (2016). Improving the effectiveness of medication review: Guidance from the health literacy universal precautions toolkit. The Journal of the American Board of Family Medicine, 29(1), 18–23. doi:10.3122/jabfm.2016.01.150163. Evidence Level III.
World Health Organization. (1972). International drug monitoring: The role of national centres. Report of a WHO meeting. Retrieved from http://whqlibdoc.who.int/trs/WHO_TRS_498.pdf. Evidence Level V.